News | January 27, 2023
Sun Pharma launches SEZABY in the US for treatment of neonatal seizures
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
Granules now have a total of 53 ANDA approvals from USFDA
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
Subscribe To Our Newsletter & Stay Updated
